While the pharmacology of sugammadex has been extensively reviewed, there is limited literature regarding its use in specific clinical settings. Several case reports describe its use in patients with the potential for postoperative respiratory dysfunction; in the settings of myasthenia gravis, Duchenne muscular dystrophy and myotonic dystrophy. We describe the use of sugammadex in a patient with severe bronchiectasis related to cystic fibrosis who required neuromuscular block for percutaneous endoscopic gastrostomy insertion. The use of rocuronium for neuromuscular block was preferred in order to avoid the potential complications associated with the use of suxamethonium. However, we wished to ensure complete neuromuscular block reversal for this short duration procedure in this high-risk patient and also to avoid the side-effects of traditional reversal agents. We therefore planned in advance to use sugammadex for neuromuscular block reversal, and this approach proved successful. Overall, the combination of rocuronium and sugammadex improved perioperative surgical and anaesthetic management in this patient.
Postoperative residual curarisation and obstructive pulmonary disease are risk factors for postoperative pulmonary complications 1, 2 . Such complications may contribute to significant patient morbidity, as well as having implications in terms of prolonging the stay in the post-anaesthesia care unit, unplanned intensive care unit admission and prolonging hospital stay [3] [4] [5] . Patients requiring neuromuscular block (NMB) for short duration procedures such as endoscopy are potentially at risk for postoperative residual curarisation if non-depolarising muscle relaxants are used and are incompletely reversed. This might occur if cholinesterase inhibitors are used before there has been sufficient return of neuromuscular function 1 . In addition, the use of anticholinesterases could be considered relatively contraindicated in patients with severe respiratory disease, because of the risks of precipitating bronchospasm and bronchorrhoea. The alternative, suxamethonium, would expose patients to the risks of depolarising block as well as the possibility of a phase II block if repeated doses are required. Mivacurium is also not an ideal drug with the possibility of histamine release, the risk of prolonged apnoea with plasma cholinesterase deficiency, and the potential need for reversal with anticholinesterases.
The modified gamma-cyclodextrin, sugammadex, is a selective relaxant-binding agent which can reverse profound levels of rocuronium-induced NMB. Its pharmacology has been reviewed extensively elsewhere [6] [7] [8] [9] . The use of the combination of rocuronium and sugammadex to provide NMB for short duration procedures in patients with significant respiratory disease could improve the safety and efficiency when managing these cases. We describe the use of this anaesthetic technique in a patient with cystic fibrosis awaiting lung transplantation, who was scheduled for insertion of a percutaneous endoscopic gastrostomy (PEG) tube.
CASE HISTORY
The consent of the patient was obtained for this case report. A 34-year-old woman with cystic fibrosis on the waiting list for lung transplantation was scheduled for insertion of a PEG tube. Her weight was 43 kg and body mass index 17.7. Her echocardiogram was normal other than a mild elevation of her pulmonary artery pressure, and she had no hepatic disease. PEG insertion was required for continuous nocturnal enteral feeding in an attempt to improve her nutritional status prior to lung transplantation. Local anaesthesia and sedation was considered inappropriate, because of concerns regarding the potential for intraoperative respiratory embarrassment, and to minimise the risk of pulmonary aspiration. In addition, the patient had expressed a strong preference for general anaesthesia.
She had been admitted 10 days prior to the procedure because of an acute infective exacerbation of her cystic fibrosis. With intensive pharmacotherapy and physiotherapy she improved, but still had significant sputum production on the day of the procedure.
The patient received no premedication other than her usual medications and nebulisers until reaching the anaesthetic bay, when she received midazolam 1.0 mg intravenously. Following institution of standard monitoring, she was preoxygenated and anaesthesia was induced with propofol 90 mg and alfentanil 1 mg. Rocuronium 30 mg was given for muscle relaxation. Her trachea was intubated and anaesthesia was maintained with sevoflurane in air and oxygen with an FiO 2 of 60%. Pressure-controlled ventilation was used as a protective measure against barotrauma. Neuromuscular function was monitored with a nerve stimulator (Innervator 252, Fisher & Paykel, Auckland, New Zealand) applied to the ulnar nerve at her right wrist.
The procedure lasted 20 minutes and was uneventful. We administered paracetamol 1.0 g intravenously for analgesia, and the PEG insertion site was infiltrated with 10 ml 0.5% bupivacaine with adrenaline 1:200,000 by the surgeon. At the end of the procedure neuromuscular function assessment showed a train-of-four count of two. Subsequently, sugammadex 200 mg was administered intravenously. Within 60 seconds full return of neuromuscular function was achieved, with no fade on double-burst or tetanic stimulation. Postoperatively she was pain free and alert with good upper airway tone and immediately demonstrated a strong cough, expectorating several plugs of tenacious sputum. Oxygen saturations were well maintained in the mid-90s on nasal prong oxygen and she returned to the ward after 30 minutes in the post-anaesthesia care unit.
DISCUSSION
We describe the use of sugammadex to reverse NMB in a patient with severe cystic fibrosis-induced bronchiectasis. We preferred the use of NMB with endotracheal intubation and controlled ventilation in this setting to improve the surgical conditions and hence shorten the duration of the procedure, to minimise the risk of aspiration, ensure adequate oxygenation, prevent hypercapnia in a patient with possible pulmonary hypertension and to prevent coughing. We chose to use rocuronium for NMB in our patient with significant cystic fibrosis-related lung disease primarily because the use of sugammadex for reversal would avoid the risk of postoperative residual curarisation, and circumvent the risks associated with the use of either suxamethonium or neostigmine. Postoperative residual curarisation in a patient with severely limited pulmonary reserve can precipitate a rapid respiratory decompensation with significant consequences, including the need for urgent re-intubation. It is an important risk factor for respiratory morbidity and mortality in the postoperative period 2,3 .
Cystic fibrosis is the most common lethal genetic disease in the Caucasian population 10 . Respiratory disease accounts for approximately 90% of the morbidity and mortality of cystic fibrosis patients 10 . This can make the anaesthetic management challenging due to the associated impaired mucociliary clearance promoting mucous plugging, chronic infection, bronchiectasis and pulmonary hypertension 11 . Pleural blebs are common and pneumothoraces can be recurrent and difficult to treat 11 . Hepatobiliary disease is also common and cirrhosis is another major cause of mortality in these patients. In patients with hepatic disease and ascites there is a greater risk of postoperative respiratory compromise, and the potential for significant pharmacokinetic disturbances that would influence anaesthetic drug choice 11 .
We chose general anaesthesia with endotracheal intubation and controlled ventilation for PEG insertion in this setting for several reasons. The primary reason was patient refusal of sedation and local anaesthesia. However, we were also concerned about the level of sedation required for PEG insertion and the risk for intraoperative respiratory compromise in a patient with significant respiratory disease. Moreover, we wanted to minimise the potential for aspiration, which would have severe consequences in a patient with marginal respiratory function. Although this patient had no significant pulmonary hypertension, the control of P a CO 2 in this setting was another potential advantage.
In order to provide optimal anaesthetic and surgical conditions, we preferred a technique utilising NMB. This would also avoid the need for topical local anaesthesia to the larynx, and minimise the risk of barotrauma with any coughing associated with recurrent stimulation of the laryngopharynx with the endoscope. We used rocuronium to provide NMB
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Anaesthesia and Intensive Care, Vol. 39, No. 2, March 2011 because we could use sugammadex for immediate and complete reversal of NMB. This would guarantee the return of a strong cough reflex and allow early extubation without the risk of postoperative residual curarisation. Moreover, the use of sugammadex for reversal avoided the need for the administration of neostigmine, and thus eliminated the risk of precipitating bronchorrhea and bronchospasm in our patient with severe obstructive pulmonary disease. This approach enabled us to maximise patient safety and facilitate an expeditious recovery. Prior to the introduction of sugammadex we would have used suxamethonium for such a case. The use of sugammadex allows rocuronium to be used to replace suxamethonium in this setting and thus avoids all the potential complications associated with the use of suxamethonium.
Sugammadex can be used to reverse even profound levels of rocuronium-induced NMB 8 . It forms an inactive inclusion complex with free steroidal relaxant that is rapidly cleared via renal excretion without being metabolised 7, 12, 13 . In a patient with cystic fibrosis and liver disease there is the potential for plasma cholinesterase deficiency, which could result in prolonged block if suxamethonium or mivacurium were used. The use of rocuronium and sugammadex would be beneficial in this setting because sugammadex is not contraindicated in liver disease.
There are several other clinical settings where the use of sugammadex has improved the perioperative management of patients requiring neuromuscular block. Myasthenia gravis is a prototypical disease ideally suited to neuromuscular block with rocuronium with sugammadex reversal, and has been demonstrated to be a safe technique in several reports 14, 15 . This approach avoids the potential complications associated with suxamethonium use, allows for cholinesterase inhibitor medication to be continued perioperatively without the risk of precipitating a cholinergic crisis at reversal and eliminates the potential risk of residual neuro-muscular block and subsequent need for postoperative respiratory support 14, 15 .
There are also reports of the use of rocuronium and sugammadex in patients with disorders of skeletal muscle 16, 17 . In the setting of myopathies, suxamethonium use risks hyperkalaemia and rhabdomyolysis, whereas in myotonic dystrophies there is the risk of prolonged contractions. Moreover, the use of non-depolarising muscle relaxants in these diseases is associated with unpredictable levels of block and duration of action. Avoiding suxamethonium and the non-depolarising muscle relaxants which require reversal with anticholinesterases, other than rocuronium, avoids these complications.
With regard to a cost-benefit analysis, the expense of the drug in this setting (approximately A$185 per 200 mg ampoule) can be justified in a patient at greater risk of postoperative pulmonary morbidity, which might result in an increased length of stay and/or an unplanned admission to the intensive care unit 4 .
We have demonstrated that the combination of rocuronium and sugammadex can be used to provide ideal intra-and postoperative conditions for shortduration procedures in patients with cystic fibrosis and end-stage lung disease. This approach would be of greater benefit in the presence of concomitant pulmonary hypertension and/or liver disease. We recommend that this anaesthetic technique be considered in patients with severely impaired respiratory function requiring intubation and early extubation, and in particular where the use of suxamethonium or traditional reversal agents are relatively or absolutely contraindicated.
